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Identification of methotrexate as a 
heterochromatin-promoting drug
Andre C. Loyola, Lin Zhang, Robin Shang, Pranabananda Dutta, Jinghong Li & Willis X. Li  
Heterochromatin is a tightly packed form of DNA involved in gene silencing, chromosome segregation, 
and protection of genome stability. Heterochromatin is becoming more recognized in tumor 
suppression and may thus serve as a potential target for cancer therapy. However, to date there 
are no drugs that are well established to specifically promote heterochromatin formation. Here, we 
describe a screening method using Drosophila to identify small molecule compounds that promote 
heterochromatin formation, with the purpose of developing epigenetic cancer therapeutics. We 
took advantage of a Drosophila strain with a variegated eye color phenotype that is sensitive to 
heterochromatin levels, and screened a library of 97 FDA approved oncology drugs. This screen 
identified methotrexate as the most potent small molecule drug, among the 97 oncology drugs 
screened, in promoting heterochromatin formation. Interestingly, methotrexate has been identified 
as a JAK/STAT inhibitor in a functional screen, causing reduced phosphorylation of STAT proteins. 
These findings are in line with our previous observation that unphosphorylated STAT (uSTAT) promotes 
heterochromatin formation in both Drosophila and human cells and suppresses tumor growth in mouse 
xenografts. Thus, Drosophila with variegated eye color phenotypes could be an effective tool for 
screening heterochromatin-promoting compounds that could be candidates as cancer therapeutics.
In eukaryotic cells, DNA is folded with histone and non-histone proteins in order to form chromatin. 
Nucleosomes, the basic units of chromatin consist of 146 bp of DNA wrapped around a histone octomer core 
and linker histone protein H1, the core being made up of two copies of H2A, H2B, H3 and H4 histone proteins. 
This chromosomal template is the foundation for many important cellular processes, such as gene transcription, 
DNA repair and recombination1,2. Generally, chromatin is found in two different assortments, euchromatin and 
heterochromatin. In 1928, Heitz first distinguished between these different chromosomal states cytologically by 
observing the differential staining of chromatin at interphase. Euchromatin stains lightly at interphase, repre-
senting a less condensed, accessible and transcriptionally active form of chromatin, while heterochromatin stains 
more strongly and is believed to be a more condensed, inaccessible and transcriptionally silent chromatin1,2.
Heterochromatin, a condensed and transcriptionally silent form of chromatin, can be further divided into two 
categories: constitutive and facultative heterochromatin. Constitutive heterochromatin domains occur in regions 
that are highly dense in repetitive DNA elements and possess structural importance. These regions remain con-
densed throughout the cell cycle. They are typically found at centromeres and telomeres and help to facilitate 
separation of chromosomes during mitosis and protect the ends of chromosomes from deterioration, respec-
tively. Facultative heterochromatin domains are important for development and the chromatin state of these 
regions can change in response to cellular signals and gene activity1,2. An example of facultative heterochromatin 
is X-chromosome inactivation in female mammals, a phenomenon in which one of the X chromosomes is con-
densed as facultative heterochromatin and formed into what is known as a Barr body3.
Various processes, including methylation of CpG islands and post-translational modification of histone pro-
teins, are associated with the dynamic transitions of chromatin states1,2. A “histone code” has been described 
in which particular posttranslational modifications can dictate the chromosomal state4. Tri-methylation of his-
tone 3 lysine 9 (H3K9me3) and recruitment of HP1 chromo domain proteins is well established to be associated 
with heterochromatin and epigenetic silencing1,2. These proteins are indicators and markers for heterochromatin 
formation.
It has become increasingly evident that heterochromatin is relevant to cancer development. It has been shown 
that in certain biological contexts, HP1 reduction or loss can lead to progression of various types of tumors5,6, 
which could conceivably be due to changes in genomic stability and derepression of genes that normally should 
be silent. Decreased HP1 levels, which lead to loss of heterochromatin, are also evident in cancer cell lines5. In 
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addition, it has been shown that BRCA1, a tumor suppressor gene well established to be associated with breast 
and ovarian cancer, prevents tumor formation through heterochromatin mediated silencing7. Retinoblastoma 
(Rb) tumor surpressor, a protein that suppresses transcription of E2F genes upon DNA damage in order to pre-
vent the division of damaged cells, also mediates its effects through stabilizing heterochromatin8–12.
We have previously identified a non-canonical JAK-STAT pathway in which un-phosphorylated STAT pro-
motes and stabilizes heterochromatin by binding to the HP1 chromodomain protein13–15. We have further shown 
that increasing global heterochromatin levels through expressing HP1a or unphosphorylatable STAT5A can 
suppress colon cancer growth using a mouse xenograph model. Interestingly, many genes down-regulated by 
STAT5A and HP1a in common have previously been shown to be overexpressed in or be drivers of human can-
cers, although genes involved in proliferation and cell death are not significantly affected16. These results support 
the idea that heterochromatin may offer a unique target for human cancers and could offer a treatment that is 
associated with less side effects compared with the cytotoxic oncology drugs.
For the purpose of identifying compounds that promote heterochromatin formation and for further research 
as candidates for cancer therapy, we designed and performed a simple screen for small-molecule compounds that 
can promote heterochromatin formation in Drosophila, which is an inexpensive in vivo system for drug discovery. 
These compounds will serve as lead molecules for developing epigenetic cancer drugs in the future.
Results
Screening of Oncology Set III using DX1 flies for heterochromatin-promoting drugs. To iden-
tify heterochromatin-promoting drugs, we sought to develop a screening method using Drosophila, an inexpen-
sive in vivo system (Fig. 1). To this end, we obtained from the National Cancer Institute (NCI) Developmental 
Therapeutics Program (DTP) a small-molecule drug library, Oncology Set III, consisting of 97 FDA approved 
oncology drugs (Table S1). We screened this library using the DX1 strain of Drosophila melanogaster. DX1 flies 
contain seven tandem copies of a P[mini-white+] reporter transgene inserted into a euchromatic region of the 2nd 
chromosome, which induce heterochromatin formation at the insertion locus due to the repetitive nature of the 
transgene copies, resulting in variegated expression of the P[mini-white+] reporter transgenes in white−/− (w−/−) 
genetic background17,18. The white+ gene encodes the transporter that carries precursors of the red and brown 
pigments into developing eyes during pupation, resulting in red colored eyes when adult flies emerge; flies lacking 
the white+ gene have white eyes19. Thus the amount of red pigmentation in DX1 flies is proportional to the level 
of the white+ gene products from the P[mini-white+] transgene. Due to the metastable nature of heterochromatin 
induced at the P[mini-white+] tandem repeats, transcription of P[mini-white+] and thus the degree of variega-
tion in the eye color of DX1 flies is sensitive to heterochromatin levels. Increasing heterochromatin levels leads 
to more variegation, less mini-white+ expression and overall red eye pigmentation; decreasing heterochromatin 
levels has the opposite effects, resulting in increased red eye pigmentation14,15,17,18. Thus, the levels of red pigmen-
tation in DX1 flies can serve as a convenient readout of heterochromatin levels in vivo.
We screened the Oncology Set III library based on the assumption that compounds that promote hetero-
chromatin should cause more variegation in the eye color in DX1 flies and thus reduced red eye pigmentation, 
as has been previously reported14,15,17,18. For screening, we crossed DX1/CyO male flies to w1118, a commonly 
Figure 1. Drug screen using DX1 Drosophila. (A) Diagram depicting using Drosophila to screen for 
heterochromatin-promoting small molecule compounds. Three w1118/Y; DX1/CyO males and three virgin w1118 
were crossed at room temperature and allowed to lay eggs for two days. Parent flies were then removed and 60 µl 
of 33% DMSO in water with 10 µM compound was pipetted onto food two days and four days after crosses were 
first set up. The eye phenotype of w1118/Y; DX1/+ F1 male progeny were then scored. (B) Eye phenotype scoring 
scale. Representative pictures representing the score assigned to flies based on eye color variegation as the 
following. 1: mostly white with light spots of red/orange scattered in <10% total surface area. 2: Patches of red 
spots in >10% but <30% of the surface area. 3: Red spots in 50% of surface area. 4: Red spots range from 50% to 
70% of eye surface. 5: Red spots occupy >70% of the eye surface.
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used w−/− strain in an otherwise wild-type genetic background. The F1 generation was raised in the presence of 
individual drugs, and the F1 w1118; DX1/+ adult male flies emerged were scored for their red eye color (Fig. 1; see 
Methods).
Identification of methotrexate as a heterochromatin-promoting drug. We scored each F1 w1118/Y; 
DX1/+ adult male fly on a scale from 1 to 5, 1 being most variegated and 5 being least variegated (Fig. 1). We then 
averaged the scores of all the F1 w1118/Y; DX1/+ males in each vial. Three trials were done per compound and 
were represented in a bar graph (Fig. 2A). We identified hit drugs as compounds that received a score that was 
two standard deviations below the mean of the control, which were exposed to solvent only (33% DMSO in H2O). 
The control flies received a mean score of 3.82 with a standard deviation of 0.67. Therefore a drug that receives a 
score different from the control score by more than two standard deviations would be considered a hit. The drug 
that caused the most variegation in this set was methotrexate (4-aminopteroylglutamic acid), with a code name 
E7 in Plate 1 of the drug library, which received a score of 2.43, less than 2.48 or two standard deviations from the 
control mean of 3.82 (Fig. 2). Methotrexate was the only drug that received a score two standard deviations below 
that of the control among all the 97 Oncology Set III drugs screened. We thus pursued methotrexate further as a 
heterochromatin-promoting drug.
Methotrexate promotes heterochromatin formation and reduces overproliferation caused by 
JAK overactivation. To confirm that methotrexate indeed promotes heterochromatin formation, we exam-
ined the levels of heterochromatin mark, histone H3 trimethylated at lysine 9 (H3K9me3), after treating larvae 
with methotrexate. Using immunostaining with anti-H3K9me3 antibodies, we found that H3K9me3 levels were 
higher in 3rd instar larval salivary gland cells of methotrexate-treated larvae when compared with control larvae 
treated with solvent only (Figs 3A,B and S1A). Drosophila larval salivary glands contain large cells with prom-
inent heterochromatin foci, which allow easy visualization and heterochromatin levels and morphology, as we 
have previously reported14,15. Heterochromatin levels can also be revealed by HP1 immunostaining, as we have 
previously shown14. Indeed, larval salivary gland nuclei show significantly larger HP1-positive heterochromatin 
area after methotrexate treatment than control (Figs 3C,D and S1B). The effects of methotrexate treatment on 
H3K9me3 levels are similar to those resulting from genetically altering JAK/STAT signaling, as we have previ-
ously shown14,15. Lastly, using Western blotting, we confirmed that methotrexate treatment causes an increase 
in levels of H3K9me3 in treated larvae (Fig. 3G). Thus, we are able to confirm at cellular and protein level, using 
immunostaining, that methotrexate promotes heterochromatin formation.
Methotrexate is one of the first chemotherapy agents used for cancer treatment, and it is also used as an 
immunosuppresant to treat rheumatoid arthritis20,21. Methotrexate is believed to be an antimetabolite that acts as 
a competitive inhibitor of dihydrofolate reductase (DHFR)22. Interestingly, in a screen for small molecules that 
Figure 2. Identification of methotrexate as a heterochromatin-promoting drug. (A) Screen of Oncology Set 
III. Triplicates of each sample were performed represented on bar graph. Control is represented as a red bar. (B) 
Bar graph of E7 and Control. Average score of E7 was 2.43 and average score of control was 3.80. (C) Structure 
of methotrexate, coded as E7 in the library plate (see Table S1). (D) Representative pictures of the eyes of E7 
(methotrexate) and control DX1 flies.
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modulate JAK/STAT signaling using cells, methotrexate was identified as a JAK/STAT pathway inhibitor, which 
reduces both STAT reporter gene expression in Drosophila cells and STAT5 phosphorylation in human cells23.
To test the effects of methotrexate on JAK/STAT signaling in flies, we used transgenic flies that overexpress 
the JAK/STAT ligand Unpaired (Upd) in the developing eye (GMR > Upd), resulting in larger eyes when adult 
flies emerge (Fig. 3E)14,24. We found that, treating the larvae with methotrexate at the same concentration that 
causes increased heterochromatin, reduced the eye size of GMR > Upd flies (Fig. 3F). This result is consistent 
with the idea that methotrexate reduces JAK/STAT signaling. However, we cannot rule out the possibility that the 
observed reduction in GMR > Upd fly eyes was due to decreased cell proliferation caused by inhibition of DHFR 
by methotrexate, as previously known22. Nonetheless, taken together with our previous finding that uSTAT pro-
motes heterochromatin formation13,15, it is possible that methotrexate reduces pSTAT levels and thus increases 
relative uSTAT levels, resulting in higher levels of heterochromatin.
Figure 3. Effects of methotrexate on heterochromatin and cell proliferation. (A,C,G) Flies were raised on 
food with or without methotrexate at the indicated concentrations (10 µM) in 33%DMSO. Salivary glands 
from 3rd instar larvae were immunostained with anti-H3K9me3 (A) or anti-HP1 (C) and photographed with 
a compound microscope. Heterochromatin levels were quantified as the ratio of H3K9me3-positive area 
to the area of the nucleus. Representative images are shown. (G) Total protein was extracted from 3rd instar 
larvae without or with methotrexate treatment at the indicated concentrations, and was subjected to SDS-
PAGE, following by blotting with antibodies specific for H3K9me3, H3, or α-Tubulin. (B,D) Quantification 
of H3K9me3 (B) or HP1 (D) immunostaining as the ratio of antibody-positive area (dark brown) to the area 
of the nucleus (light brown). Error bars are standard deviations. *Indicates p < 0.05 by Student’s t-Test. (E) 
Flies carrying the GMR-Gal4 and UAS-Upd transgenes were raised at 25 °C on food with or without 10 µM 
methotrexate. Adult male flies were photographed to show the eyes. (F) Eye volumes were quantified by 
measuring at O.D. 480 nm the amount of red pigments in fly heads.
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Discussion
Heterochromatin formation represents a potential epigenetic tumor suppression mechanism2,5,7,16. Compounds 
that promote heterochromatin formation are therefore desirable as candidate cancer therapeutic agents. In 
order to identify new heterochromatin-promoting small molecule drugs, we performed a simple screen using 
Drosophila, taking advantage of the DX1 strain that exhibits a heterochromatin-dependent eye color variegation 
phenotype (Fig. 1). Upon screening a small library of 97 drugs, we identified a small molecule drug, methotrexate, 
as causing the highest increase in variegation, which is significantly different from control (Fig. 2).
Interestingly, as a first-generation cancer chemotherapy drug and known to be a dihydrofolate reductase 
(DHFR) inhibitor, methotrexate has more recently been identified as a specific JAK/STAT pathway inhibitor, 
resulting in a reduced level of pSTAT without changing total STAT levels, therefore causing a relative increase 
in uSTAT levels23. We have previously shown that reducing pSTAT and increasing uSTAT levels promote het-
erochromatin formation as a non-canonical function of STAT13,15,16. Thus, the identification of methotrexate as 
a JAK/STAT inhibitor23 and as a heterochromatin-promoting drug (this study) is line with our research demon-
strating that uSTAT promotes heterochromatin formation15,16.
Our screening method is relatively straightforward and easy to carry out. However, there is a caveat when 
calculating the drug concentration used in the screening. We added drug solutions at 10 µM to the top of the food 
media, which is in semisolid state. The effective drug concentration is expected to remain in a steep gradient, 
with the top portion close to 10 µM and limited penetration to the bottom of the food. On the other hand, larvae 
mostly stay on and consume the top portion of the food. Thomas et al. have shown that methotrexate inhibits 
STAT phosphorylation in cultured cells at concentrations ranging from 0.01 to 50 µM with minimal toxicity23. 
Thus, we assume that our drugging regimen for methotrexate effectively inhibited STAT phosphorylation without 
strong toxic effects. Indeed, at 10 µM concentration, we did not observe much lethality in larvae treated with any 
of the 97 drugs we used in screening. However, when added at 100 µM concentration, methotrexate did cause 
lethality to the larvae. Thus, 10 µM is a tolerable concentration for screening these small-molecule drugs.
We will expand the screening effort for heterochromatin-promoting substances to a larger pool of small mol-
ecule compounds using the Drosophila variegated eye phenotype. Upon discovery of compounds that are sus-
pected to promote heterochromatin formation, we will identify the mechanisms by which these drugs accomplish 
this in future research. We will also investigate the ability and the underlying mechanisms by which these com-
pounds to suppress cancer.
Methods
Small-molecule drug library. Compound Libraries were obtained through the National Cancer Institute 
(NCI) Developmental Therapeutics Program. We screened Oncology Set III, a set of 97 oncology drugs that have 
been previously approved by the US Food and Drug Administration (FDA). The compounds were delivered in 
96-well polypropylene (PP) microtiter plates with 60 compounds per plate. The plates were stored dry at −20 °C 
and contained 0.20 µMol of compound + 1 µL of glycerol. 19 µL of DMSO was added to each well to obtain 20 µl 
of 10 mM stock solutions.
Drosophila screening method. DX1 flies were kindly provided by James Birchler (University of 
Missouri)17,25. Three w1118/Y; DX1/CyO male flies and three virgin w1118 female flies were crossed in a 25 × 95 mm 
food vial with 9 ml of standard food (Bloomington recipe). Flies were allowed to lay eggs for two days at room 
temperature. Parent flies were then removed from the vial and 60 µl of a 10 µM drug solution was pipetted onto 
food on day two, and another 60 µl of the same drug solution was added again on day four after crosses were set 
up (Fig. 1A). All drug compounds were prepared by diluting the original stock (10 mM in DMSO) to a 10 µM 
final concentration by dissolving in 33% DMSO in water. Since the fly food is in solid state, the drug solution is 
expected to remain in a deep gradient, with the top portion close to 10 µM and limited penetration to the bottom 
of the food. For control treatment, only 33% DMSO in water was used.
Scoring was carried out 2 days after the F1 flies emerge, all w1118/Y; DX1/+ heterozygous males, identified by 
lacking the CyO dominant curly wing phenotype, were scored for eye color on a scale of 1 to 5 (see Fig. 1B). (The 
choice of 1 to 5 scale was based on Sun Tzu’s writing in the Art of War, “The colors do not exceed five, but the 
changes of the five colors can never be completely seen.”) Color scale is determined by the following rules.
 1. Mostly white with light spots of red/orange scattered in <5% total surface area.
 2. Patches of red spots in >5% but <25% of the surface area.
 3. Red spots in >25% to <50% of surface area.
 4. Red spots range from >50% to <75% of eye surface.
 5. Red spots occupy >75% of the eye surface.
Triplicates of each cross were performed. Eye color for all F1 males of the w1118/Y; DX1/+ genotype were 
assigned from 1 to 5 as above. Color index was calculated as the average of all the males scored. Representative 
pictures were taken using a digital camera through microscope lens.
Eye pigmentation measurement. To measure red eye pigment levels, the heads of 40 male flies (2 days 
old, raised at 25 °C) of appropriate genotypes were severed and homogenized in methanol (1 ml, acidified with 
0.1% HCl). Eye pigmentation was represented as the absorbance of the supernatant at 480 nm.
Salivary gland immunostaining and western blotting. The salivary gland dissection and 
whole-mount immunostaining procedure was adopted from published protocols26 and as previously described14. 
Briefly, salivary glands were dissected from wandering 3rd instar larvae by grasping and pulling the mouth hook 
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with forceps in Drosophila Ringer’s solution. The larvae had been treated with drug solution or control solvent, 
as described above. The dissected salivary glands were fixed in 4% paraformaldehyde and 0.3% Triton-X in phos-
phate buffered salient (PBS) for 20 min, were then blocked with 1% bovine serum albumin (BSA) in PBS, and 
were incubated with primary antibodies at 4 °C for overnight and then with HRP-conjugated second antibodies. 
Histochemical staining was done following routine procedures. Stained salivary gland tissues were photographed 
with a Zeiss epifluorescence microscope with Nomarski optics. Images were cropped and minimally processed 
with Adobe Photoshop.
Mouse monoclonal anti-HP1 (C1A9; 1:50) was from Developmental Hybridoma Bank (University of Iowa). 
Rabbit antibodies against H3K9me3 (07-442; 1:250) with cross species specificities were from MilliporeSigma 
(Burlington, MA). HRP conjugated anti-rabbit IgG secondary antibodies were used in whole-mount immunos-
taining and Western blotting.
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